Nebenwirkungen · Fuzeon
Fuzeon 90 mg/ml powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 7
HOS-112428 · Präparat HOS-093667
The majority of patients had no change in the toxicity grade of any laboratory parameter during the study except for those listed in Table 4. Through week 48, eosinophilia [greater than the Upper Limit of Normal of > 0.7 x 109/l] occurred at a higher rate amongst patients in the Fuzeon containing group (12.4 patients with event per 100 patient-years) compared with OB alone regimen (5.6 patients with event per 100 patient-years). When using a higher threshold for eosinophilia (>1.4 x 109/l), the patient exposure adjusted rate of eosinophilia is equal in both groups (1.8 patients with event per 100 patient- years).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-23T14:24:00Z · SHA-256 e89d317a43084b88c577a5e2fa9e8f995c2b6672ed7d5ae08eb316c0043e17cf · Passage 9f1006e4475830f1a13b0b5a4e89c67c6c7c4a991b1fda2a13720414b315ef53 · Zeichen 7285–7905 im Abschnitt